BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38696253)

  • 21. Using a continuum of hybrid effectiveness-implementation studies to put research-tested colorectal screening interventions into practice.
    Green BB; Coronado GD; Schwartz M; Coury J; Baldwin LM
    Implement Sci; 2019 May; 14(1):53. PubMed ID: 31142348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of a standard intervention versus a navigated intervention on colorectal cancer screening use in primary care.
    Lairson DR; Dicarlo M; Deshmuk AA; Fagan HB; Sifri R; Katurakes N; Cocroft J; Sendecki J; Swan H; Vernon SW; Myers RE
    Cancer; 2014 Apr; 120(7):1042-9. PubMed ID: 24435411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost Effectiveness of Mailed Outreach Programs for Colorectal Cancer Screening: Analysis of a Pragmatic, Randomized Trial.
    Kapinos KA; Halm EA; Murphy CC; Santini NO; Loewen AC; Skinner CS; Singal AG
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2383-2392.e4. PubMed ID: 35144024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.
    Gupta S; Coronado GD; Argenbright K; Brenner AT; Castañeda SF; Dominitz JA; Green B; Issaka RB; Levin TR; Reuland DS; Richardson LC; Robertson DJ; Singal AG; Pignone M
    CA Cancer J Clin; 2020 Jul; 70(4):283-298. PubMed ID: 32583884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of screening strategies for colorectal cancer.
    Barzi A; Lenz HJ; Quinn DI; Sadeghi S
    Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mailed FIT (fecal immunochemical test), navigation or patient reminders? Using microsimulation to inform selection of interventions to increase colorectal cancer screening in Medicaid enrollees.
    Davis MM; Nambiar S; Mayorga ME; Sullivan E; Hicklin K; O'Leary MC; Dillon K; Hassmiller Lich K; Gu Y; Lind BK; Wheeler SB
    Prev Med; 2019 Dec; 129S():105836. PubMed ID: 31635848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health plan-based mailed fecal testing for colorectal cancer screening among dual-eligible Medicaid/Medicare enrollees: Outcomes of 2 program models.
    Baldwin LM; Coronado GD; West II; Schwartz MR; Meenan RT; Vollmer WM; Petrik AF; Shapiro JA; Kulkarni-Sharma YR; Green BB
    Cancer; 2022 Jan; 128(2):410-418. PubMed ID: 34586630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bundling Colorectal Cancer Screening Outreach with Screening for Social Risk in Federally Qualified Health Centers: A Stepped-Wedge Implementation-Effectiveness Study.
    Kruse GR; Percac-Lima S; Barber-Dubois M; Davies ME; Gundersen DA; Ho O; Mascioli L; Munshi M; Perry S; Singh D; Thomas A; Emmons KM; Haas JS
    J Gen Intern Med; 2024 May; 39(7):1188-1195. PubMed ID: 38332440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
    Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
    Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.
    Karlitz JJ; Fendrick AM; Bhatt J; Coronado GD; Jeyakumar S; Smith NJ; Plescia M; Brooks D; Limburg P; Lieberman D
    Popul Health Manag; 2022 Jun; 25(3):343-351. PubMed ID: 34958279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Test Kit on Colorectal Cancer Screening Rates: A Randomized Clinical Trial.
    Goshgarian G; Sorourdi C; May FP; Vangala S; Meshkat S; Roh L; Han MA; Croymans DM
    JAMA Netw Open; 2022 Feb; 5(2):e2146863. PubMed ID: 35119462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
    Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
    Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy.
    Ladabaum U; Ferrandez A; Lanas A
    Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2765-76. PubMed ID: 20810603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Centralized Program with Stepped Support Increases Adherence to Colorectal Cancer Screening Over 9 Years: a Randomized Trial.
    Green BB; Anderson ML; Cook AJ; Chubak J; Fuller S; Meenan RT; Vernon SW
    J Gen Intern Med; 2022 Apr; 37(5):1073-1080. PubMed ID: 34047921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.